EFFICACY AND SAFETY OF GUSELKUMAB TN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

被引：0
|
作者：
Coates, Laura C. [1 ]
Gossec, Laure [2 ]
Theander, Elke [3 ]
Bergmans, Paul [4 ]
Neuhold, Marlies [5 ]
Karyekar, Chetan S. [6 ]
Shawi, May [6 ]
Noel, Wim [5 ]
Schett, Georg [7 ]
McInnes, Iain B. [8 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[2] Sorbonne Univ, Dept Rheumatol, Paris, France
[3] Janssen Sci Affairs LLC, Dept Immunol, Solna, Sweden
[4] Janssen, Dept Biostat, Breda, Netherlands
[5] Janssen Sci Affairs LLC, Dept Immunol, Brussels, Belgium
[6] Janssen Global Serv LLC, Dept Immunol, Horsham, PA USA
[7] FAU Erlangen Nurnberg, Dept Internal Med 3, Nurnberg, Germany
[8] Univ Glasgow, Dept Immunol, Glasgow, Lanark, Scotland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2021年 / 27卷
关键词：
DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PANLAR2021
引用
收藏
页码：S106 / S107
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
    Coates, L. C.
    Gossec, L.
    Theander, E.
    Bergmans, P.
    Neuhold, M.
    Karyekar, C.
    Shawi, M.
    Noel, W.
    Schett, G.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 140 - 141
  • [2] Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
    Georg Schett
    Warner Chen
    Sheng Gao
    Soumya D. Chakravarty
    May Shawi
    Frederic Lavie
    Miriam Zimmermann
    Mohamed Sharaf
    Laura C. Coates
    Stefan Siebert
    Arthritis Research & Therapy, 25
  • [3] Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
    Ogdie, Alexis
    Merola, Joseph F.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Scher, Jose U.
    Lafferty, Kimberly Parnell
    Chan, Daphne
    Chakravarty, Soumya D.
    Langholff, Wayne
    Wang, Yanli
    Choi, Olivia
    Krol, Yevgeniy
    Gottlieb, Alice B.
    BMC RHEUMATOLOGY, 2024, 8 (01)
  • [4] DESIGNING A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF GUSELKUMAB DOSING INTERVAL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION
    Ogdie, A.
    Merola, J. F.
    Mease, P. J.
    Ritchlin, C. T.
    Scher, J. U.
    Chan, D.
    Chakravarty, S. D.
    Langholff, W.
    Choi, O.
    Krol, Y.
    Rowland, K.
    Gottlieb, A. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1567 - 1568
  • [5] Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study (vol 25, 150, 2023)
    Schett, Georg
    Chen, Warner
    Gao, Sheng
    Chakravarty, Soumya D.
    Shawi, May
    Lavie, Frederic
    Zimmermann, Miriam
    Sharaf, Mohamed
    Coates, Laura C.
    Siebert, Stefan
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [6] Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial
    Alexis Ogdie
    Soumya M. Reddy
    Sarah H. Gillespie
    M. Elaine Husni
    Jose U. Scher
    Karen Salomon-Escoto
    Jonathan Kay
    Brent A. Luedders
    Jeffrey R. Curtis
    Alisa J. Stephens Shields
    Soumya D. Chakravarty
    Cinty Gong
    Jessica A. Walsh
    Trials, 26 (1)
  • [7] Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
    Coates, Laura C.
    Gossec, Laure
    Theander, Elke
    Bergmans, Paul
    Neuhold, Marlies
    Karyekar, Chetan S.
    Shawi, May
    Noel, Wim
    Schett, Georg
    McInnes, Iain B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (03) : 359 - 369
  • [8] A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITOR(S)
    Nash, P.
    Kirkham, B.
    Okada, M.
    Rahman, P.
    Combe, B.
    Adams, D. H.
    Kerr, L. N.
    Lee, C. H.
    Shuler, C. L.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 135 - 135
  • [9] Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Merola, Joseph
    Landewe, Robert
    McInnes, Iain B.
    Mease, Philip J.
    Ritchlin, Christopher
    Tanaka, Yoshiya
    Asahina, Akihiko
    Behrens, Frank
    Gladman, Dafna
    Gossec, Laure
    Warren, Richard
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3169 - 3171
  • [10] Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
    Gossec, Laure
    Baraliakos, Xenofon
    Galloway, James
    Erik, Lars
    Oke, Vilija
    Sfikakis, Petros
    Rampakakis, Emmanouil
    Sharaf, Mohamed
    Lavie, Frederic
    McInnes, Iain
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2807 - 2809
12345